Related Experiment Video
Updated: Aug 6, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Testosterone Dysregulation and Erectile Dysfunction Associated With Teprotumumab Infusions: A Case Report
Sri Meghana Konda1, Lisa Y Lin1,2, Suzanne K Freitag1
1Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Ophthalmic Plastic and Reconstructive Surgery
|July 20, 2026
Summary
Teprotumumab infusions may cause reversible testosterone dysregulation and erectile dysfunction in patients with thyroid eye disease. Symptoms resolved after treatment completion but recurred with subsequent teprotumumab courses.
Area of Science:
- Endocrinology
- Ophthalmology
- Pharmacology
Background:
- Thyroid eye disease (TED) is an autoimmune condition affecting the orbits.
- Teprotumumab is a novel biologic agent approved for active TED treatment.
- Potential side effects of teprotumumab require ongoing investigation.
Purpose of the Study:
- To report a case of testosterone dysregulation and erectile dysfunction associated with teprotumumab therapy.
- To investigate the relationship between teprotumumab infusions and hypogonadal symptoms.
Main Methods:
- A case report of a 52-year-old male with active TED.
- Monitoring of testosterone levels and erectile function during and after teprotumumab treatment.
- Administration of testosterone replacement therapy for hypogonadal symptoms.
Main Results:
- The patient experienced recurrent erectile dysfunction and low testosterone levels during each course of teprotumumab.
- Testosterone levels normalized post-treatment, and symptoms resolved.
- Testosterone replacement therapy improved hypogonadal symptoms and normalized levels during treatment.
Conclusions:
- Teprotumumab infusions are likely associated with reversible testosterone dysregulation and erectile dysfunction.
- Monitoring endocrine function is crucial in patients receiving teprotumumab.
- Further studies are needed to elucidate the mechanism of this adverse effect.
